All In Biotech

Drug Trial Radar · NCT05764590

A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients

A Phase 2, Randomized, Open-Label, Active-Controlled, Multicenter Study to Evaluate the Safety and Serum Phosphorus Lowering Effect of AP-306 in Chronic Kidney Disease Patients Receiving Maintenance Hemodialysis With Hyperphosphatemia

Last checked: Nov 19, 2026Latest source record: Jan 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

55

Actual

Start

Feb 20, 2023

Primary completion

Aug 25, 2023

Study completion Sep 14, 2023

Sponsor

Lead sponsor
Alebund PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Mar 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn about the following questions in the patients receiving maintenance hemodialysis with elevated blood phosphorus: * How much effect AP-306 has assessed by blood phosphorus lowering; * How safe and tolerable AP-306 is. Participants will receive either following treatments: * AP-306, and * Sevelamer carbonate.

Conditions

  • Chronic Kidney Diseases
  • Hyperphosphatemia

Interventions

  • AP-306Drug

    A blood phosphorus lowering drug with a novel mechanism

  • Sevelamer CarbonateDrug

    A phosphate binder

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of AP-306 assessed by serum phosphorus loweringTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.